Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Inozyme Pharma Inc.

Headquarters: Boston, MA, United States of America
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Doug Treco Treco, PhD
Number Of Employees: 67
Enterprise Value: $107,463,725
PE Ratio: -0.62
Exchange/Ticker 1: NASDAQ:INZY
Exchange/Ticker 2: N/A
Latest Market Cap: $64,220,900

BioCentury | Aug 25, 2023
Management Tracks

John Orwin named chairman at Cargo

Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
BioCentury | May 9, 2023
Management Tracks

Laronde’s Cagnoni to head R&D at Incyte

Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
BioCentury | Mar 23, 2023
Management Tracks

Treco to succeed Bolte as CEO of Inozyme

Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Aug 18, 2022
Management Tracks

PerkinElmer vet Mock becomes CFO at Moderna

Plus Huertas named CMO at Kriya, and updates from Opko Health and Foresite Labs
BioCentury | Jun 8, 2022
Management Tracks

NIBR’s Marks joins GV as entrepreneur-in-residence

Plus new venture partner and promotions at Arch, and updates from IQVia, Emergence and more
BioCentury | Mar 9, 2022
Management Tracks

Oxford spinout MiroBio adds Keswani as CMO, promotes Murray to CSO

Plus updates from Centessa, Teon, AnchorDx, Pillar and more
BioCentury | Nov 9, 2021
Management Tracks

Maraganore joins board at Beam

Plus: new CBO, board member at Caribou, Nordic, GT Biopharma and more
BioCentury | May 20, 2021
Management Tracks

Lurie named U.S. director at CEPI; plus Seres, Celularity, Rain, Senti and Cybrexa

Nicole Lurie was named U.S. director of the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership to develop vaccines for future epidemics. Lurie was assistant secretary
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai in 1987, has served as
BioCentury | Nov 11, 2020
Management Tracks

Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more

Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John
Items per page:
1 - 10 of 23